Research Abstracts Online
January 2010 - March 2011
University of Minnesota Twin Cities
Academic Health Center
Masonic Cancer Center
PI: Deepali Sachdev
Gene Profiling and In Vivo Imaging in Targeting the Metastatic Phenotype Regulated by the Type I Insulin-Like Growth Factor Receptor in Breast Cancer
Metastatic breast cancer is incurable, but new targets that inhibit metastases offer hope to patients. The type I insulin-like growth factor receptor (IGF1R) stimulates growth and proliferation of breast cancers. Its role in regulating metastasis is not clearly delineated. This researcher has discovered that, in some metastatic breast cancer cells, IGF1R does not affect tumor growth but regulates the development of pulmonary metastases in athymic mice. Several reagents against IGF1R are in phase I and II clinical trials for breast and other cancers.
The hypothesis is that IGF1R regulates metastases independent of tumor growth. Thus, response to anti-IGF1R therapy will need to be measured by methods other than shrinkage in tumor size. The objective of this research was to determine if the expression patterns of a set of genes can predict response to reagents targeting IGF1R in the metastatic setting. The specific aims of this project were: to determine if a genetic profile distinguishes tumors where IGF1R regulates the metastatic phenotype independent of tumor growth and if response to anti-IGF1R therapy can be predicted by changes in the expression of a set of genes; to validate the metastatic signature against other metastatic breast cancer cell lines where IGF1R regulates motility; and to identify the mechanisms by which IGF1R enhances metastasis.